The invention of auto-injectors is a boon to the patients who
suffer from allergies. There is a strong rise in development of affordable
generic models. This could increase the availability
of low cost auto injectors around the world.
Browse full research report @ http://www.radiantinsights.com/research/emea-europe-middle-east-and-africa-auto-injectors-industry-2017
What are Auto-Injectors?
Auto-injectors are the pen-like medical devices used to treat
anaphylactic shock. These devices find applications for the treatment of
diabetes, Rheumatoid Arthritis (RA), and Multiple Sclerosis (MS). Disposable
and reusable are the two major types of auto-injectors. These devices have a
built-in safety mechanism to prevent needlestick injuries. This preventive
measure has been implemented to deter drug addicts. Surge in allergy attacks
among school going kids has led to their mandatory presence on school campuses.
Its transition in delivery route from subcutaneous to intradermal points can
lead to rapid drug delivery.
Latest Developments
The drastic surge in prices of Mylan’s Epi-Pen led to the
launch of generic auto-injectors. These affordable devices provided a big relief
to the people dependent on them. Companies such as Cigna and CVS Health have
decided to capture the manufacturing gap by launching enhanced versions of
their existing products at economical rates.
Development of biologic therapies to treat immediate pain and
provide relief has been possible with the help of auto-injectors. The European
Commission allowed the use of sarilumab in combination with methotrexate to
treat RA patients. This drug can be administered with disposable syringes for
patients who are unresponsive to other drugs.
Wearable injectors are a booming trend within the industry
which has promising potential. They can be used to dispense large volumes of
drugs that are deemed incompatible with disposable or reusable injectors.
Although in its developmental stage, its use can extend to treating
cardiovascular, neurological, and autoimmune diseases.
Market Overview
The auto-injectors market in the EMEA region is expected to
attain high revenue by 2022, according to a report available on Radiant
Insights, Inc. It is driven by rising cases of multiple sclerosis, rheumatoid
arthritis, and anaphylaxis. The market is expected to exhibit a significant
CAGR during the forecast period (from 2012 to 2022). High demand for
auto-injectors to provide relief from anaphylactic shock can further support
the expansion.
Reusable auto-injectors are used to deliver growth hormones,
while disposable auto-injectors can deliver biologic drugs for chronic
diseases. Clinics, hospitals, and others are the major application areas.
Immense demand from hospitals can impel market over the forecast period.
Clinics offer educational courses to enlighten first-time users. Notable market
players are Ypsomed Holding AG; Mylan, Inc.; Becton, Dickinson and Company (BD);
and Sanofi S.A.
Request free sample at:
No comments:
Post a Comment